Health and Human Services Department, National Institutes of Health
The National Institute of Diabetes and Digestive and Kidney Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the invention embodied in the patents and patent applications listed in the Supplementary Information section of this notice to Nulyn Science ("Nulyn"), a company located in Paris, France.
Document Headings Document headings vary by document type but may contain the following: the agency or agencies that issued and signed a document the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to the agency docket number / agency internal file number the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details. Department of Health and Human Services National Institutes of Health AGENCY: National Institutes of Health, HHS. ACTION: Notice. SUMMARY: The National Institute of Diabetes and Digestive and Kidney Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the invention embodied in the patents and patent applications listed in the Supplementary Information section of this notice to Nulyn Science (“Nulyn”), a company located in Paris, France. DATES: Only written comments and/or applications for a license which are received by the National Institute of Diabetes and Digestive and Kidney Diseases' Technology Advancement Office on or before September 17, 2026 will be considered. ADDRESSES: Inquiries and comments relating to the contemplated Exclusive Patent License should be directed to: Betty B. Tong, Ph.D., Senior Licensing and Patenting Manager, NIDDK Technology Advancement Office, Telephone: (301)-451-7836; Email: tongb@mail.nih.gov . SUPPLEMENTARY INFORMATION: Intellectual Property 1. Australian Patent Application No. 2020239920 filed March 9, 2020, entitled “Method for Improving Insulin Sensitivity” [HHS Reference No. E-081-2019-0-AU-01]; 2. South Korean Patent Application No. 10-2021-7033113 filed March 9, 2020, entitled “Method for Improving Insulin Sensitivity” [HHS Reference No. E-81-2019-0-KR-01]; 3. New Zealand Patent App…
Citation: 91 FR 56458
